Children who needed renal replacement therapy at the time of VAD implantation were rare, sicker, and had lower one-year survival than other VAD patients. But after accounting for other factors, the therapy itself was not independently linked to mortality.
In a prospective study of 265 males with Duchenne Muscular Dystrophy, nearly 30% of those with moderate or severe heart dysfunction were not receiving full consensus-directed cardiac therapy, and most did not reach target medication doses—highlighting the need to optimize treatment strategies as cardiac disease becomes a leading cause of death in DMD.
Cardiac Medication Use in ACTION for Duchenne Muscular Dystrophy Cardiomyopathy Read More »
An expert opinion statement, addressing a critical gap in cardiac care for Duchenne muscular dystrophy – providing thorough recommendations for the initiation and titration of cardiac medications based on disease progression and patient response.
Partnership of cardiologists with gene transfer therapy prescribers is essential to identifing patient-specific considerations that might influence risk for adverse cardiac events.
Can early improvement after VAD implant positively affect outcomes? This study describes the clinical status of pediatric patients supported with a VAD and determines how clinical status at 1-month follow-up
Early Improvement in Clinical Status Following VAD Implantation in Children Read More »
